ImmunityBio Shares Surge on Strong Product Revenue and Global Expansion

ImmunityBio's Anktiva revenue surged 700% in 2025, driving stock swings. The biotech secured key global approvals but posted a Q4 loss amid high R&D spend.

ImmunityBio's stock experienced significant volatility this week following the release of its latest financial results and a detailed roadmap for international growth. The company's flagship product, Anktiva, demonstrated remarkable revenue growth for 2025, though the broader financial picture shows the biotech firm remains in a development phase.

Financial Performance: Rapid Revenue Growth Amid Ongoing Investment

The standout figure from ImmunityBio's report was the net product revenue for Anktiva, which reached approximately $113 million for the full year 2025. This represents a staggering increase of roughly 700% compared to the prior year. Momentum continued into the final quarter, with Q4 net product sales hitting $38.2 million, a sequential quarterly increase of 20%.

The company's bottom-line loss was narrower than analysts had anticipated. The GAAP loss per share for the fourth quarter was -$0.06, beating the consensus estimate of -$0.10. However, the overall business is not yet profitable. The net loss attributable to common shareholders for Q4 was $61.9 million, slightly higher than the $59.2 million loss reported for the same period a year earlier.

A significant rise in research and development expenses contributed to the loss, climbing to $63.9 million from $35.2 million. This jump was partly due to a one-time $14 million impairment charge on property and equipment. On a positive note, selling, general, and administrative (SG&A) costs decreased to $38.7 million from $41.7 million. As of December 31, 2025, ImmunityBio held $242.8 million in cash, cash equivalents, and marketable securities.

Stock Price Sees Extreme Swings

The market reaction to the news was dramatic. Shares initially jumped around 13% on Monday to $9.83. The rally extended into Tuesday, with the stock hitting an intraday high of $12.43—a new 52-week peak—before reversing course sharply. At one point, the stock was down 18.7% from the previous close of $11.55, trading around $11.09 in the morning session.

Adding fuel to the initial optimism, analysts at H.C. Wainwright raised their price target for ImmunityBio from $10 to $15 on Monday. Reports indicate the stock has roughly quintupled in value since the start of 2026, driven by a series of positive corporate updates.

Global Regulatory Approvals Fuel Optimism

A core driver for investor sentiment is the company's rapidly expanding international footprint. ImmunityBio announced that Anktiva has now secured approvals or authorizations in four regulatory regions encompassing 33 countries:

• United States: FDA approval (April 2024)
• United Kingdom: MHRA authorization (July 2025)
• Saudi Arabia: Accelerated approval (January 2026) for bladder and lung cancer
• European Union: Conditional marketing authorization from the EC (February 2026) for 27 EU states plus Iceland, Norway, and Liechtenstein

The Saudi Arabian authorization is particularly notable, as it is the first jurisdiction worldwide to approve Anktiva in combination with checkpoint inhibitors for metastatic non-small cell lung cancer (NSCLC), marking its first indication beyond bladder cancer.

Commercial Strategy and Upcoming Catalysts

The company is framing its expansion within a three-year plan that positions Anktiva as the cornerstone of its "Cancer BioShield" platform. Key upcoming milestones include:

• Bladder Cancer (BCG-unresponsive): Plans to submit a Biologics License Application (BLA) in the fourth quarter of 2026.
• Lung Cancer (NSCLC): Pursuing accelerated approvals in multiple regions, with FDA discussions planned for 2026.
• Lymphoma: Initiating a Phase 2 study for a chemotherapy-free CAR-NK cell therapy (ResQ215B) in February 2026.
• Recombinant BCG: An FDA meeting is scheduled for March 2026 in the United States.

Commercially, ImmunityBio is building infrastructure to support its growth. It has established partnerships with BioPharma and Cigalah Healthcare for Saudi Arabia and the MENA region. In Europe, it will operate through an Irish subsidiary and its distribution partner Accord Healthcare, with plans to deploy over 100 commercial personnel across more than 30 European countries.

Investors are now focused on two near-term events: the FDA meeting on recombinant BCG in March and the targeted BLA submission for BCG-unresponsive bladder cancer in late 2026. The coming quarters will reveal how effectively the recent wave of international approvals translates into sustained product revenue growth.